Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

ONO PHARMACEUTICAL : ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients (20.2KB)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/17/2012 | 07:58am CEST

April 17, 2012


President and Representative Director: Gyo Sagara,

Code No.: 4528 at the 1st section of the Tokyo / Osaka Stock Exchange

INQUIRIES: Kinya Morimoto, Executive Officer, Director, Corporate Communications

ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients

Ono Pharmaceutical Co., Ltd. announced today that the global Phase II study (DreaMS*) of ONO-4641 in development for the indication of multiple sclerosis (MS) was completed and met the primary endpoint.
The study was a double-blind placebo-controlled study conducted in 11 countries including North America, Europe and Japan in patients with relapsing-remitting multiple sclerosis. A total of 407 patients between the ages of 18 and 55 with relapsing-remitting MS were randomized to receive placebo or one of 3 active doses of ONO-4641 once daily for 26 weeks.
Patients were included in the study if they had two or more relapses in the two years prior to the study, one or more relapses within the year prior to the study or one or more new MS-related brain lesions, also known as Gd-enhancing lesions, detected on MRI within three months prior to the study. For the primary endpoint of the study, MRIs were performed every four weeks from 10 to 26 weeks, 5 times.
At the end of the study, patients taking 0.05, 0.10, or 0.15 mg of ONO-4641 had 82 percent, 92 percent and 77 percent fewer Gd-enhancing brain lesions (all p<0.0001), respectively, compared to placebo.
Adverse events appeared to be generally dose related. Of note was a slower heartbeat and atrioventricular blocks associated with the initiation of treatment, which were asymptomatic, transient and did not require ONO-4641 discontinuation. Other notable adverse events included liver enzyme elevations. In addition, Grade 4 lymphopenia, which is an abnormally low level of lymphocytes in the blood, occurred in 4 percent of patients receiving the 0.15 mg dose of ONO-4641 and in 1 percent of those receiving the 0.10 mg dose.
Detailed data will be presented at the American Academy of Neurology's 64th Annual Meeting in
New Orleans April 21 to April 28, 2012.
Ono has granted Merck KGaA, Darmstadt, Germany, an exclusive license for development and commercialization of ONO-4641 in countries around the world except Japan, Korea and Taiwan under the agreement entered into October, 2011.

* DreaMS: Drug Research EvaluAtion for Multiple Sclerosis

<Reference> About ONO-4641
ONO-4641 is a sphingosine-1-phosphate (S1P) receptor agonist which keeps lymphocytes in lymph nodes and thereby inhibits the infiltration of lymphocytes into lesions. The compound is therefore expected to be a drug for the treatment of auto-immune diseases such as multiple sclerosis, which is regarded as an intractable disease.

About Multiple Sclerosis

Multiple sclerosis is a chronic neurological disorder accompanying by diverse and severe neurological symptoms such as paralysis and numbness of limbs, gait disorders, visual disorders, and dysuria. Although there are no specific factors known to be responsible for the onset and relapses of the disease, it is thought to be an autoimmune disease that, because of some triggers, one's own body is improperly recognized as foreign and is attacked by lymphocytes, which have an essential role in the immune system for protection from foreign substances such as viruses and bacteria. Most patients are diagnosed between the ages of 20 and 40, and women tend to suffer disproportionately more from this disease compared to men. In Japan, around 14,500 people suffer from this disorder. It is estimated that there are at least 350,000 MS patients in the US and about 2.5 million globally.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
06/05ONO PHARMACEUTICAL : Opdivo Plus Chemotherapy Showed Improved Progression-Free S..
06/05ONO PHARMACEUTICAL : Opdivo (nivolumab) 3 mg/kg Demonstrates Sustained, Superior..
06/05ONO PHARMACEUTICAL : Array BioPharma Announces Additional Median Overall Surviva..
06/04ONO PHARMACEUTICAL : Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimuma..
05/31Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Cons..
05/30ONO PHARMACEUTICAL : Announcement on Establishment of Immune-mediated Inflammato..
05/25ONO PHARMACEUTICAL : and BMSKK Receive Approval for Opdivo® and Yervoy® Combinat..
05/25ONO PHARMACEUTICAL : Notice to Convene the 70th Ordinary General Shareholders' M..
05/07ONO PHARMACEUTICAL : European Medicines Agency Validates Bristol-Myers Squibb&rs..
05/07ONO PHARMACEUTICAL : Karyopharm Announces Positive Top-Line Data from Phase 2b S..
More news
News from SeekingAlpha
04/303 THINGS IN BIOTECH, APRIL 29 : Bristol-Myers Widens, Ono Takes On Pheo, BrainSt.. 
03/23Alzheon Files To Raise $80 Million In U.S. IPO 
03/14Ono Pharma exercises option for Merus Biclonics technology for autoimmune bis.. 
2017Ono Pharmaceutical Needs To Reinvest Its Windfall 
2017YOUR DAILY PHARMA SCOOP : Axovant's Promised Upside, Gilead's Whistleblower Trou.. 
Financials ( JPY)
Sales 2019 279 B
EBIT 2019 -
Net income 2019 53 113 M
Finance 2019 92 785 M
Yield 2019 1,72%
P/E ratio 2019 26,00
P/E ratio 2020 21,01
EV / Sales 2019 4,87x
EV / Sales 2020 4,31x
Capitalization 1 453 B
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Technical analysis trends ONO PHARMACEUTICAL CO., LT
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 3 218  JPY
Spread / Average Target 20%
EPS Revisions
Gyo Sagara President & Representative Director
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director & Executive Vice President
Isao Ono Director & Managing Executive Officer
Kei Sano Director & Senior Executive Officer